LEUCHEMIX DRUG DISCOVERY APPROACH

Leuchemix takes advantage of a synergistic group of committed and talented, founding scientists led by an experienced CEO and Board that brings together a wide-array of talents necessary for the success of any drug discovery enterprise. By utilizing the respective skills of these scientists and business leaders, Leuchemix plans to develop its drugs without the usual costs associated with conventional drug discovery and development.

Leuchemix’ takes advantage of the numerous naturally occurring cyotoxic agents that have been identified over decades of cancer research. Importantly, the company focuses on novel anti-tumor compounds derived from natural sources but with structural backbones that are amenable to modification via medicinal chemistry and library construction. These sources of compounds have been largely ignored in the traditional libraries built by the large pharmaceutical companies. The company has licensed novel anti-tumor compounds as well as libraries assembled for cytotoxic and anti-leukemic activity. These compounds allow for the rapid generation of lead and optimized compounds together with the rapid implementation of pre-clinical pharmaceutical development. The Company has established a clinical network for testing its new compounds together with the necessary development and regulatory expertise.

The adult leukemias such as Acute Myelogenous Leukemia (AML) are poorly served in the marketplace today and a clear need exists for the development of novel products. The company has access to a full library of leukemic patient samples and has characterized key components of these tumor cells. These samples allow for assessing the anti-tumor activity of compounds on the source of hematological cancers, allow for the determination of a therapeutic window by comparison with normal cells and offer a unique opportunity to perform discovery on the system most relevant to human clinical trials. Importantly, this means that drug discovery is performed on patient samples. The comparison of the effects on primary isolates from leukemic and normal patients also gives a highly valuable first toxicology screen for any potential drug. Additionally, from our extensive molecular analyses of the leukemic state we have an insight into molecular pathways that are potentially relevant to other tumor types. As such, we use the adult leukemias as a launching pad for our studies in both larger market hematological malignancies such as Multiple Myeloma and Lymphoma as well as solid tumor diseases.

LEUKEMIA INFORMATION AND LINKS

For more information and research on Leukemia we offer the following links for your reference:

The Leukemia & Lymphoma Society

The National Cancer Institute - Leukemia information home page

WIKIPEDIA - Leukemia Information Page